

Open For Enrollment

Protocol	Age Group	Key Criteria	PI & Location
YKP3089C040: Open-Label Safety and Efficacy Study of Cenobamate (YKP3089) in Pediatric Subjects with Partial-onset (Focal) Seizures	2-<4	<ul style="list-style-type: none"> • Dx POS • 1-3 AED with stable dose in past 30 days • Cannot be on Sabril (6 month washout) • 1 Seizure in 4 weeks 	<ol style="list-style-type: none"> 1. Dr. Segal: Hackensack 2. Dr. Mahalingam: Morristown
YKP509C003: A Randomized, Double-blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Carisbamate (YKP509) as Adjunctive Treatment for Seizures Associated with Lennox-Gastaut Syndrome in Children and Adults, with Optional Open-Label Extension	4-55	<ul style="list-style-type: none"> • Documented Hx of LGS with first seizure <11 years of age • 1-4 AEDs with stable dose in past 30 days • At least 8 drop seizures with potential to fall during the 4 week baseline period • Cannot have status epilepticus within 12 weeks prior to visit 1. 	<ol style="list-style-type: none"> 1. Dr. Segal: Hackensack
XPF-010-303: A Randomized, Double-blind, Placebo-Controlled, Multicenter, Phase 3 Study to Evaluate the Safety, Tolerability, and Efficacy of XEN1101 as Adjunctive Therapy in Primary	>12	<ul style="list-style-type: none"> • Dx with PGTCs • 1-3 AED with stable dose in past 30 days • Must have 3 PGTCs during 8 week of screening period • Cannot have status epilepticus within 12 months prior to visit 1 	<ol style="list-style-type: none"> 1. Dr. Asfi Rafiuddin: Hackensack. Sub -I: Dr. Segal

Please Reach out to Research Team if you need more information.

Research Direct line: 551-497-5000.

Hardik Rana: hrana@epilepsygroup.com; Ryan Zahn: rzahn@epilepsygroup.com; Anbudoss Devapiriyam: adevapiriyam@epilepsygroup.com

Generalized Tonic-Clonic Seizures			
<p>PRAX-562-221: A Phase 2, Double-Blind, Randomized Clinical Trial to Explore the Safety, Tolerability, Efficacy, and Pharmacokinetics of PRAX-562 in Pediatric Participants with Developmental and Epileptic Encephalopathies Followed by an Open-Label Extension</p>	2-18	<ul style="list-style-type: none"> Documented variant in SCN2A with onset of seizure occurring in first 3 month of life or diagnosis of SCN8A-DEE supported by both clinical and genetic findings. 8 countable motor seizures in 4 weeks Cannot be on more than 2 sodium channel blocking ASMs 	<p>1. Dr. Segal: Hackensack</p> <p>All study visits can be done from home if caregiver cannot come on site</p>
<p>LP352-302: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Investigate the Efficacy, Safety, and Tolerability of LP352 in the Treatment of Seizures in Children and Adults with Dravet Syndrome</p>	2-65	<ul style="list-style-type: none"> Dx of Dravet Syndrome 4 Countable motor seizures per month in past 3 months prior to visit 1 1-4 ASMs with stable dose for 4 weeks prior to visit 1 Cannot have Hx of hospitalization requiring mechanical ventilation due to status epilepticus within 3 months prior to visit 1 	<p>1. Dr. Mahalingam: Morristown</p>

Please Reach out to Research Team if you need more information.

Research Direct line: 551-497-5000.

Hardik Rana: hrana@epilepsygroup.com; Ryan Zahn: rzahn@epilepsygroup.com; Anbudoss Devapiriyam: adevapiriyam@epilepsygroup.com

<p>LP352-301: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Investigate the Efficacy, Safety, and Tolerability of LP352 in the Treatment of Seizures in Children and Adults with Developmental and Epileptic Encephalopathies</p>	2-65	<ul style="list-style-type: none"> • Dx Of DEE(other than LGS) with onset of seizure < 5 years of age • LGS with onset of seizure < 8 years of age • Countable motor seizures per month in past 3 months prior to visit 1 • 1-4 ASMs with stable dose for 4 weeks prior to visit 1 • Cannot have Hx of hospitalization requiring mechanical ventilation due to status epilepticus within 3 months prior to visit 1 	1. Dr. Mahalingam: Morristown.
<p>XPF-010-301: A Randomized, Double-Blind Placebo-controlled multicenter Phase 3 Study to Evaluate the safety tolerability and efficacy of XEN1101 as adjunctive Therapy in focal -onset Epilepsy</p>	18-75	<ul style="list-style-type: none"> • DX with POS (Focal) • HX of only focal aware without motor seizures only will not be allowed • May be on 1 to 3 AEDS • During the 8-week baseline period must have more than 4 focal seizures within 28 days 	1. Dr. Rafiuddin: Hackensack

Please Reach out to Research Team if you need more information.

Research Direct line: 551-497-5000.

Hardik Rana: hrana@epilepsygroup.com; Ryan Zahn: rzahn@epilepsygroup.com; Anbudoss Devapiriyam: adevapiriyam@epilepsygroup.com

<p>CT-AMT-260-01: A Multi-center, Phase 1/2a, First-in-human (FIH) Study Investigating the Safety, Tolerability and Efficacy of AMT-260 in Adults with Unilateral Refractory Mesial Temporal Lobe Epilepsy (MTLE) Administered via Magnetic Resonance Imaging (MRI)-guided Convection-enhanced Delivery (CED)”</p>	<p>18-65</p>	<ul style="list-style-type: none"> • Dx of Unilateral Refractory MTLE • Willingness to Undergo Surgical Procedure • Average of 2 documented focal seizures per 30-day period for past 3 months. Cannot have any implant that is nor MRI compatible. 	<p>1. Dr. Rafiuddin: Hackensack</p>
<p>PRAX-628-321: A Double-Blind, Randomized, Multicenter, Trial Evaluating the Efficacy and Safety of PRAX-628 in Adults with Focal Seizures (POWER 1)</p>	<p>18-75</p>	<ul style="list-style-type: none"> • DX with POS (Focal) • HX of only focal aware without motor seizures only will not be allowed • May be on 1 to 3 AEDS • During the 8-week baseline period must have more than 4 focal seizures within 28 days 	<p>1. Dr. Rafiuddin: Hackensack</p>
<p>PRAX-628-212: An Open Label Clinical Trial to Evaluate the Efficacy and Safety of PRAX-628 in Adult Patients with Focal Onset or Primary Generalized Tonic-Clonic Seizures</p>	<p>18-75</p>	<ul style="list-style-type: none"> • DX with POS (Focal) or Idiopathic generalized tonic clonic seizure. • May be on 1 to 3 AEDS • During the 8-week baseline period must have more than 2 focal seizures or 1 Generalized tonic 	<p>1. Dr. Segal: Hackensack</p>

Please Reach out to Research Team if you need more information.

Research Direct line: 551-497-5000.

Hardik Rana: hrana@epilepsygroup.com; Ryan Zahn: rzahn@epilepsygroup.com; Anbudoss Devapiriyam: adevapiriyam@epilepsygroup.com

		clonic seizure within 28 days	
<p>BHV7000-302: A Phase 2/3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Efficacy, Safety and Tolerability of BHV-7000 in Subjects with Refractory Focal Epilepsy</p>	18-65	<ul style="list-style-type: none"> • DX with POS (Focal) • HX of only focal aware without motor seizures only will not be allowed • May be on 1 to 3 AEDS • During the 8-week baseline period must have more than 4 focal seizures within 28 days 	1. Dr. Rafiuddin: Hackensack
<p>BHV7000-304: A Phase 2/3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of BHV-7000 as Adjunctive Therapy in Subjects with Idiopathic Generalized Epilepsy with Generalized Tonic-Clonic Seizures, with Open-label Extension Epilepsy” (SHINE)</p>	12-65	<ul style="list-style-type: none"> • 18- 75 years old • Idiopathic Generalized Epilepsy • 3 GTC in 16 weeks • Currently taking 1-3 ASMs 	1. Dr. Rafiuddin: Hackensack
<p>YKP3089C49: Open-label Study of Cenobamate Monotherapy in Adult Subjects with Newly Diagnosed or Recurrent Partial-Onset Epilepsy</p>	18-74	<ul style="list-style-type: none"> • Newly Diagnosed patient of POS (Focal) 	1. Dr. Rafiuddin: Hackensack

Please Reach out to Research Team if you need more information.

Research Direct line: 551-497-5000.

Hardik Rana: hrana@epilepsygroup.com; Ryan Zahn: rzahn@epilepsygroup.com; Anbudoss Devapiriyam: adevapiriyam@epilepsygroup.com